HK Stocks Key Headlines: Goldman Sachs Upgrades Chinese H-Share Rating, BYD Responds to Acquisition Rumors
TechFlow reports, on November 16, citing Jin10 Data, Goldman Sachs has upgraded its investment rating for China H-shares to "Overweight." Addressing rumors about selling a Digital Power division to BYD, BYD Co., Ltd. stated there is no factual basis.
In the Hong Kong market, radiopharmaceutical company Transcenta launched its IPO today, with the subscription period running until November 19. The offer price ranges from HK$52 to HK$68 per share, comprising 6.561 million H-shares. JForce Pharmaceuticals announced that clinical research for its GFH276 combination therapy in pancreatic cancer has completed the first patient dose in both China and overseas.
Additionally, Xianbixin sublingual tablets from Simcere Pharmaceutical and zaltiretinib from InnoCare Pharma have been incorporated into the newly revised National Reimbursement Drug List. Fosun Pharma stated that several products from the company and its holding subsidiaries were newly listed, had their annotation details adjusted, or were moved to routine list management.





